Pitcairn’s Edwards Lifesciences EW Stock Holding History

Pitcairn’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,319	Closed	-$803K	–	192
2025 Q3	$803K	Sell	10,319 -1,366	-12%	-$107K	0.06%	248
2025 Q2	$914K	Sell	11,685 -2,784	-19%	-$208K	0.06%	273
2025 Q1	$1.05M	Sell	14,469 -556	-4%	-$39.8K	0.06%	261
2024 Q4	$1.11M	Sell	15,025 -7,675	-34%	-$537K	0.07%	246
2024 Q3	$1.5M	Sell	22,700 -35,970	-61%	-$2.61M	0.09%	206
2024 Q2	$5.42M	Buy	58,670 +3,156	+6%	+$279K	0.33%	51
2024 Q1	$5.3M	Sell	55,514 -4,024	-7%	-$338K	0.34%	49
2023 Q4	$4.54M	Buy	59,538 +7,470	+14%	+$520K	0.34%	49
2023 Q3	$3.61M	Buy	52,068 +319	+0.6%	+$25.6K	0.3%	55
2023 Q2	$4.88M	Buy	51,749 +843	+2%	+$73.3K	0.41%	36
2023 Q1	$4.21M	Buy	50,906 +2,420	+5%	+$190K	0.39%	39
2022 Q4	$3.62M	Sell	48,486 -2,128	-4%	-$164K	0.36%	49
2022 Q3	$4.18M	Buy	50,614 +495	+1%	+$47.6K	0.45%	33
2022 Q2	$4.77M	Buy	50,119 +1,674	+3%	+$173K	0.5%	28
2022 Q1	$5.7M	Sell	48,445 -90	-0.2%	-$10.1K	0.5%	31
2021 Q4	$6.29M	Buy	48,535 +30	+0.1%	+$3.5K	0.4%	32
2021 Q3	$5.49M	Sell	48,505 -2,406	-5%	-$275K	0.38%	34
2021 Q2	$5.27M	Sell	50,911 -1,012	-2%	-$95.4K	0.35%	39
2021 Q1	$4.34M	Buy	51,923 +770	+2%	+$65.1K	0.31%	44
2020 Q4	$4.67M	Sell	51,153 -1,114	-2%	-$92.4K	0.36%	41
2020 Q3	$4.17M	Buy	52,267 +308	+0.6%	+$24K	0.35%	40
2020 Q2	$3.59M	Sell	51,959 -1,258	-2%	-$89.4K	0.35%	43
2020 Q1	$3.35M	Sell	53,217 -5,163	-9%	-$372K	0.4%	35
2019 Q4	$4.54M	Buy	58,380 +1,266	+2%	+$98.9K	0.42%	34
2019 Q3	$4.19M	Buy	57,114 +846	+2%	+$59.4K	0.41%	33
2019 Q2	$3.46M	Buy	56,268 +153	+0.3%	+$9.25K	0.35%	41
2019 Q1	$3.58M	Sell	56,115 -2,046	-4%	-$117K	0.39%	36
2018 Q4	$2.97M	Sell	58,161 -4,122	-7%	-$209K	0.33%	42
2018 Q3	$3.61M	Buy	62,283 +7,542	+14%	+$369K	0.37%	36
2018 Q2	$2.66M	Buy	54,741 +6,720	+14%	+$314K	0.28%	45
2018 Q1	$2.23M	Sell	48,021 -3,414	-7%	-$148K	0.24%	51
2017 Q4	$1.93M	Sell	51,435 -1,596	-3%	-$58.6K	0.19%	65
2017 Q3	$1.93M	Sell	53,031 -5,565	-9%	-$212K	0.22%	58
2017 Q2	$2.31M	Buy	58,596 +2,274	+4%	+$83K	0.28%	48
2017 Q1	$1.77M	Buy	56,322 +35,229	+167%	+$1.1M	0.21%	67
2016 Q4	$659K	Sell	21,093 -2,115	-9%	-$68.5K	0.08%	182
2016 Q3	$933K	Sell	23,208 -663	-3%	-$25K	0.12%	135
2016 Q2	$794K	Buy	23,871 +1,872	+9%	+$64K	0.1%	145
2016 Q1	$647K	Buy	21,999 +1,113	+5%	+$30.7K	0.08%	195
2015 Q4	$550K	Buy	+20,886	New	+$542K	0.06%	220

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Pitcairn's EW Position: Q4 2025 in Review

Pitcairn sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 10,319 shares — an estimated $803K sold.

Pitcairn first reported a position in EW in Q4 2015 and held it in 40 quarters. The position peaked at $6.29M in Q4 2021. 1,313 funds tracked by Wall St. Rank hold EW as of Q4 2025.

Pitcairn reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
Pitcairn sold 10,319 Edwards Lifesciences shares in Q4 2025, an estimated $803K.
Pitcairn first reported a position in Edwards Lifesciences in Q4 2015 and held it in 40 quarters.
Pitcairn's Edwards Lifesciences position peaked at $6.29M in Q4 2021.
1,313 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Pitcairn's 13F filing for Q4 2025.